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Aim: To study the redox-dependent mechanism of antiradical, antitumor and antimetastatic action of L-arginine hydrochloride 
(L-Arg) and coenzyme Q10 (CoQ10) in vivo. Materials and Methods: The study was performed on С57Вl mice with transplanted 
Lewis lung carcinoma treated by intraperitoneal injections of L-Arg at low or high doses (60 and 360 mg/kg body weight), 
CoQ10 (0.2 and 1.2 mg/kg body weight) or their combinations. Electron paramagnetic resonance was applied for analysis of mito-
chondrial electron transport chain, СoQ10 levels, free iron (FI), the level of NO, and the rate of superoxide radical generation. The 
activity of matrix metalloproteinase (MMP)-2 and -9 in tumor tissue was determined by zymography method in polyacrylamide 
gel. Results: Administration of L-Arg at high doses caused an inhibition of tumor growth by 48 ± 8.0%, increase of superoxide 
radical generation rate and NO levels to a value of 1.23 ± 0.14 аnd 2.26 ± 0.31 nm/g tissue · min, and decreased activity 
of MMP-2 and -9 (3.55 ± 0.8 and 4.8 ± 1.0 r.u., respectively). Treatment with L-Arg at low doses stimulated tumor growth and 
increased the levels of MMP-2 and -9 activities (8.44 ± 2.7 and 9.8 ± 3.1 r.u., respectively). Administration of СoQ10 at high 
doses significantly decreased superoxide radical generation rate to the values of 0.44 ± 0.09 nm/g tissue · min, levels of free iron 
and NO, and caused tumor growth inhibition by 54 ± 11.3%. The combined use of L-Arg and СoQ10 at high doses caused tumor 
growth inhibition by 51 ± 7.4% compared to Lewis lung carcinoma-bearing untreated animals (р < 0.05). Conclusions: Administra-
tion of L-Arg and СoQ10 caused the dose-dependent effect on the rate of generation of superoxide radicals, level of ubisemyquinone, 
complexes NOFeS-proteins, levels of FI and NO. L-Arg at low doses positively modulated MMP-9 activity that promoted tumor 
progression. Upon combined use of L-Arg and СoQ10, superoxide radicals and NO form the redox state that causes decrease 
of MMP-2, -9 activities with consequent inhibition of tumor invasion and metastasis.
Key Words: L-arginine, coenzyme Q10, superoxide radical, nitric oxide, matrix metalloproteinase, Lewis lung carcinoma.
One of the approaches to search for innovative anti-
cancer agents with fundamentally different mechanism 
of action is the use of compounds — donors of nitric oxide 
(NO), which can modulate the levels of NO and other 
regulators of transport rate of electrons in the electron 
transport chain in mitochondria. Normally functioning 
mitochondrial metabolism is a process of fine-adjustable 
dynamic balance of thousands of anabolic and catabolic 
reactions and cell signaling systems. Since NO is the key 
signaling molecule in tumor-induced angiogenesis, its 
antitumor activity can be manifested at least due to its 
ability to regulate angiogenic pathway [1–5].
Coenzyme Q10 (CoQ10) plays the key role in the 
mechanism of functioning of the power gene rating 
cell system and in the formation of redox potential 
in mitochondria through the regulation of superoxide 
radical generation to control gene transcription and 
cellular and extracellular signaling factors. Physiologi-
cal levels of CoQ10 in plasma are 0.68–1.1 µmol/l and 
are supported mainly by endogenous synthesis and 
to a lesser extent by pro ducts of exogenous origin. Ac-
tivity of CoQ10 decreases with aging as well as in various 
pathologies, including diabetes, chronic heart failure, 
myocardial infarction and cancer [6]. There is a growing 
amount of evidence in favor of the use of food additives 
with CoQ10 for prevention and treatment of pathological 
conditions, NO donors and other regulators of electron 
transport in mitochondria, including CoQ10 are explored 
as anticancer agents [7, 8]. However, mechanisms 
of their action have been studied insufficiently. The 
matrix metalloproteinases (MMPs), which play a role 
in tumor invasion and metastasis [9, 10], are redox-
dependent enzymes [11–13], therefore, they may 
be involved in the realization of anti-tumor effects 
of compounds-regulators of electron transport [14, 15].
The aim of the study was to investigate the redox-
dependent mechanism of anti-radical, antitumor and 
antimetastatic action of L-Arg and CoQ10 in vivo.
materiaLS and methodS
The study was performed on 84 С57Вl male 
mice weighting 22.4 ± 1.12 g bred in animal facility 
of R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology of the NAS of Ukraine. The 
animals were kept on a standard diet. Animal study 
protocols and operation procedures were carried out 
in accordance with the main requirements to keeping 
and working with laboratory animals and to the rules 
of local Bioethics Committee.
Lewis lung carcinoma (LLC) was used as a tu-
mor model. LLC cells (5 • 105 cells per animal) were 
transplanted subcutaneously [16]. The compounds 
(L-Arginine hydrocloride (L-Arg) (Sigma, USA), 
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CoQ10 (Sigma, USA)) were administered intraperi-
toneally daily for 10 days at low or high doses: L-
Arg — 60 and 360 mg/kg body weight; CoQ10 — 0.2 and 
1.2 mg/kg body weight. The animals were distri buted 
into 8 experimental groups; І — intact animals (n = 10); 
ІІ — tumor control (n = 11); ІІІ and ІV — animals with 
tumors treated with high (n = 12) and low (n = 10) 
doses of L-Arg, respectively; V та VІ — animals with 
tumors treated with high (n = 10) and low (n = 10) doses 
of СоQ10, respectively; VІІ and VІІІ — animals with tu-
mors treated with high (n = 10) and low (n = 10) doses 
of L-Arg and СоQ10, respectively. Animals of group II re-
ceived daily intraperitoneal injections of physiological 
saline at corresponding volume for 10 days and served 
as a positive control.
The research of the electron transport chain in mito-
chondria, СoQ10 levels in mitochondria and free iron (FI) 
in tumor cells was performed by electron paramagnetic 
resonance (EPR) method with compu terized spectrom-
eter RE-1307 using the technology of low-temperature 
stabilization of biological material (77 K). The rate of su-
peroxide radical generation by mitochondria of cells was 
determined by EPR method using a spin trap (2,2,6,6,-tet-
rametyl-4-oxypiperidine) at the room temperature 
in a special paramagnetic pure quartz cuvette. The level 
of NO in the tumor tissue was investigated by EPR using 
the Spin Traps techno logy (spin trap — diethyl dithiocar-
bamates (Sigma)) at the temperature of 77 K [13].
The activity of MMP-2 and -9 in tumor tissue was 
determined by zymography method in polyacrylamide 
gel (with addition of gelatin as a substrate) based 
on SDS-electrophoresis of proteins [17].
The tumor volume was determined by the formula 1:
V = (π/6) · D1 · D2 · D3, (1)
where V — tumor volume (mm3); D1, D2, D3 — tu-
mor length, width, and height.
The number of metastases was counted, and their 
volume — by the formula 1.
The antitumor activity of the studied compounds 
was evaluated by tumor growth inhibition: 
G% = (vc−ve)/mk · 100%, (2)
where G% — percentage of tumor growth inhibition 
by volume; vc — average tumor volume in the control; 
ve — average tumor volume in the study group.
Statistical analysis of the obtained data was 
performed with the use of Origin 7.0 program and 
Student’s t-criterion. The data were presented as the 
mean with the standard deviation (M ± SD). The differ-
ences were considered significant at p < 0.05.
reSuLtS and diScuSSion
The results of EPR study of LLC are shown in Fig. 1.
In tumor cells of group II (EPR spectrum 1) there 
were registered the low levels of free radical form 
of СoQ10 — ubisemiquinone (g = 2.00) — 0.15 ± 
0.02 r.u., Fe-S-protein N-2 (g = 1.94) responsible for 
coupling of oxidation and phosphorylation — 0.14 ± 
0.01 r.u. Also, there was noted an accumulation of high 
levels of FI (g = 2.20–2.40) — 0.86 ± 0.08 r.u., the level 
of NOFe-S-protein complexes was 0.18 ± 0.02 r.u.
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fig. 1. Effect of L-Arg and CoQ10 at high doses on mitochon-
drial electron transport chain in LLC cells: 1 — tumor of mice 
in group II; 2 — tumor of mice in group III; 3 — tumor of mice 
in group V; 4 — tumor of mice in group VII
In animals injected with L-Arg at high doses, 
nanomolar levels of NO in the tumor tissue were 
generated, what caused 2.3-fold decrease of FI le vel 
compared to that in group II (р < 0.05). Under these 
conditions, there were recorded significant increase 
of the levels of ubisemyquinone up to 0.21 ± 0.02 r.u., 
and NOFeS-proteins complexes in the mitochondrial 
electron transport chain (up to 0.48 ± 0.02 r.u.), while 
activity of FeS-protein N-2 remained unaltered (0.14 ± 
0.013 r.u.).
Administration of СoQ10 resulted in the decreased 
FI content in tumor tissue of animals (0.21 ± 0.02 r.u.) 
compared to groups II and III (р < 0.05), and increased 
formation of NO-FeS-proteins complex (0.58 ± 
0.04 r.u.). The level of ubisemyquinone in the I com-
plex of mitochondrial respiratory chain was 0.22 ± 
0.01 r.u. what was significantly lower compared with 
group II; p < 0.05); activity of FeS-protein N-2 was 
0.11 ± 0.02 r.u. CoQ10, providing mitochondria with 
ubiquinone (NADH-ubiquinone-oxidoreductase and 
succinate dehydrogenase complexes), promotes the 
restoration of oxidative phosphorylation via its eleva-
tion in the electron transport chain.
The combined therapy with L-Arg and СoQ10 resulted 
in the decrease of FI level — 0.28 ± 0.03 r.u. compared 
to group II (p < 0.05), ubisemyquinone (0.15 ± 0.01 r.u.) 
and NOFeS-proteins complexes (0.38 ± 0.04 r.u.) 
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compared to groups ІІІ and IV (p < 0.05), increase 
of FeS-protein N-2 activity — 0.14 ± 0.02 (compared 
to group IV; p < 0.05).
Fig. 2 shows the data on the rate of generation 
of superoxide radicals by LLC cells. In the tumors 
of group II the value was 0.75 ± 0.13 nm/g tissue • min, 
while in the lungs of intact animals it was equal to 0.19 ± 
0.03 nm/g tissue • min. In the case of administration 
of high doses of L-Arg, the rate of superoxide radical 
generation was 1.23 ± 0.14 nm/g tissue • min, that 
was significantly higher than corresponding values 
of group II (р < 0.05). Therapy with L-Arg at low doses 
did not influence on this index (0.78 ± 0.22 nm/g tis-
sue • min). The use of high doses of СoQ10 caused 
nearly 2-fold decrease in levels of superoxide radi-
cals (0.44 ± 0.09 nm/g tissue • min) in mitochondria 
of tumor cells compared to group II (p < 0.05). After 
administration of low СoQ10 doses this index did not 
change (0.62 ± 0.08 nm/g tissue • min). Combined 
administration of L-Arg and СoQ10 at low doses reduced 
the superoxide radical generation rate in mitochondria 
of tumor cells (0.32 ± 0.04 nm/g tissue • min) com-
pared with groups II, III, IV, VI (p < 0.05), where as high 
doses of this compounds reduced this index to 0.65 ± 
0.09 nm/g tissue • min what was lower than in group III 
(p < 0.05). Thus, the regulators of the electron transport 
rate in mitochondrial respiratory chain decreased the 
rate of superoxide radical generation to corresponding 
levels in a dose dependent manner.
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fig. 2. The rate of superoxide generation (O2·) in the mitochon-
dria of cells: 1 — lungs of intact mice; 2 — tumor control; 3 — 
tumors of mice that administered high doses of L-Arg; 4 — low 
doses of L-Arg; 5 — tumors of mice treated with high doses 
of CoQ10; 6 — low doses of CoQ10; 7 — tumors of mice treated with 
high doses of L-Arg and СoQ10 and 8 — L-Arg and СoQ10 at low 
doses. p < 0.05 compared to tumor control (group II)
Fig. 3 shows the results of the research of NO con-
tent in tumor cells. In the tumor bearing animals this 
rate was 1.95 ± 0.21 nm/g tissue • min, which ex-
ceeded the rate in the group of intact animals — 1.45 ± 
0.18 nm/g tissue • min (p < 0.05). NO level in the tumor 
after administration of high doses of L-Arg increased 
up to 2.26 ± 0.31 nm/g tissue • min versus 1.58 ± 
0.19 nm/g tissue • min in the case of low dose L-Arg 
treatment, and the difference between these indexes 
is statistically significant. The levels of NO is the cases 
of administration of high and low doses of СoQ10 were 
1.51 ± 0.12 and 1.62 ± 0.23 nm/g tissue • min, respec-
tively. Combined therapy with L-Arg and СoQ10 at high 
doses resulted in the increased level of NO up to the 
values of 2.2 ± 0.3 nm/g tissue • min compared 
with groups IV, V, VI (р < 0.05), whereas in the case 
of low dose combined treatment this index (1.47 ± 
0.09 nm/g tissue • min) was significantly lower than 
in groups II, III and VII (р < 0.05). Therefore, the NO do-
nor and its combined use with СoQ10 at high doses 
cause the significant increase of NO levels in tumor 
cells, which is a positive factor in the antitumor and 
antimetastatic therapy.
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fig. 3. The level of NO in the mitochondria of cells: 1 — lungs 
of intact mice; 2 — tumor control; 3 — tumors of mice treated 
with high doses of L-Arg; 4 — low doses of L-Arg; 5 — tumors 
of mice treated with high doses of CoQ10; 6 — low doses of CoQ10; 
7 — tumors of mice treated with high doses of L-Arg and СoQ10; 
8 — L-Arg and СoQ10 at low doses. p < 0.05 compared with tumor 
control (group II)
Administration of L-Arg at high doses causes 
an increase in NO level, augments mitochondrial dam-
age, intensificates generation of superoxide radicals, 
increases the rate of oxidation-induced mutations 
of mtDNA, and induces tumor cell apoptosis [8]. 
NO at low doses promotes tumor invasiveness, angio-
genesis and immune tolerance [1, 7]. Administration 
of СoQ10 at high doses to animals with LLC significantly 
reduced NO levels in tumor cells compared to control 
animals (see Fig. 3). Combined use of L-Arg and 
СoQ10 at low doses caused an increase of NO levels 
in tumor cells compared to group II (р < 0.05).
Summarizing the obtained information, one may 
suppose that high doses of regulators of the electron 
transport rate based on NO and СoQ10 donors cause 
correlating effects at the level of mitochondria. These 
compounds influence regulation of superoxide radical 
generation rate and NO level, and subsequently modu-
late MMP-2 and -9 activities. Activity of MMP-2 and 
-9 in tumor tissue of the control animals greatly 
exceeded these indices in the lungs of the intact ani-
mals and correlated with the values of the superoxide 
radicals generation rate by tumor cells in these groups 
of animals (Fig. 2, 4, 5). In tumors of animals injected 
with high doses of L-Arg a significant (almost 2 times; 
p < 0.05) decrease in activity of both gelatinases was 
observed compared with the control group, which 
could be a consequence of the ultrahigh rate of super-
oxide radical generation. On the contrary, low doses 
of L-Arg caused an insignificant increase in activity 
of MMP-2 in tumor tissue compared to the control 
that was due to the regulatory impact of the increase 
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in rate of superoxide radical generation in tumor cells 
of this group of animals (see Fig. 2, 4, 5). Treatment 
with both high and low doses of СоQ10 led to the sig-
nificant superoxide regulated decrease (1.7–2.3 times; 
p < 0.05) in activity of both gelatinases, compared 
to group II (see Fig. 2, 4, 5).
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fig. 4. Activity of MMP-2 (r.u.): 1 — lungs of intact mice; 
2 — tumor control; 3 — tumors of mice treated with high doses 
of L-Arg; 4 — low doses of L-Arg; 5 — tumors of mice treated 
with high doses of CoQ10; 6 — low doses of CoQ10; 7 — tumors 
of mice treated with high doses of L-Arg and СoQ10; 8 — L-Arg and 
СoQ10 at low doses. p < 0.05 compared to tumor control (group II)
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fig. 5. Activity of MMP-9 (r.u.): 1 — lungs of intact mice; 2 — 
tumor control; 3 — tumors of mice treated with high doses 
of L-Arg; 4 — low doses of L-Arg; 5 — tumors of mice treated 
with high doses of CoQ10; 6 — low doses of CoQ10; 7 — tumors 
of mice treated with high doses of L-Arg and СoQ10; 8 — L-Arg and 
СoQ10 at low doses. p < 0.05 compared to tumor control (group II)
Activity of MMP-2 and -9 in tumors of animals 
injected by both substances at high or low doses 
was significantly below the control values (p < 0.05). 
In this case (Table 1, 2) low gelatinase activity levels 
corresponded to slower primary tumor growth and 
decreased metastasis in experimental animals. In the 
control group and group of animals injected with low 
doses of L-Arg, high gelatinase activity levels were 
observed in tumor tissue along with accelerated LLC 
growth and metastasis.
Tables 1 and 2 shows the data on antitumor and 
antimetastatic activity of L-Arg and СоQ10 administered 
at low and high doses. As one may see, the antitumor 
and antimetastatic activity of L-Arg differed significantly 
depending on the level of NO in tumor cells (p < 0.05). 
Thus, high doses of the compound caused a decrease 
in the tumor volume by 48.0 ± 8.0%, while low doses 
stimulated its growth, number of metastases and their 
volume (p < 0.05). Treatment with СoQ10 at high and low 
doses resulted in inhibition of the tumor growth by 54.0 ± 
11.3 and 39.0 ± 5.4%, respectively, the difference be-
tween these indexes was insignificant. Combined ef-
fect of both compounds at high doses caused tumor 
growth inhibition by 51.0 ± 7.4%. Thus, a NO donor 
and СoQ10 showed the antitumor and antimetastatic 
activity, and the pro- and anti-tumor effect of NO de-
pended on its dose. These data were in accordance 
with those of other authors who demonstrated the dual 
effect of NO donors [1, 7, 8]. Superoxide regulated 
MMP-2 and -9 mediate anti-tumor effects of L-Arg 
and СoQ10 at the level of intercellular matrix proteolysis, 
because reduced activity of gelatinases contributes 
to inhibition of migration, dissemination of tumor cells 
and formation of metastatic centers.
Table 1. Antitumor activity of L-Arg and СoQ10
Groups  
of animals
Doses
High Low
Tumor vo-
lume, mm3
Inhibition 
of tumor 
growth, %
Tumor vo-
lume, mm3
Inhibition 
of tumor 
growth, %
Tumor control 1600 ± 95 – 1600 ± 95 –
L-Arg 832 ± 1151 48 ± 8.0 1840 ± 1251 15 ± 2.6
СоQ10 736 ± 1371 54 ± 11.3 970 ± 1121,2 39 ± 5.4
L-Arg and СоQ10 784 ± 1041 51 ± 7.4 1410 ± 992,3 12 ± 3.1
Note: 1p < 0.05 compared to tumor control (group II); 2p < 0.05 compared 
to animals treated with L-Arg; 3p < 0.05 compared to animals treated with 
CoQ10.
Table 2. Antimetastatic activity of L-Arg and СoQ10
Groups  
of animals
Doses
High Low
Number 
of meta-
stases
Volume 
of metasta-
ses, mm3
Number 
of meta-
stases
Volume 
of metasta-
ses, mm3
Tumor control 6.8 ± 3.1 139 ± 54 6.8 ± 3.1 139 ± 54
L-Arg 3.6 ± 1.1 79 ± 21 10.8 ± 1.1 212 ± 33
СоQ10 3.1 ± 2.3 76 ± 13 4.7 ± 2.31 89 ± 131
L-Arg and СоQ10 3.2 ± 1.5 78 ± 18 4.0 ± 2.51,2 99 ± 181
Note: 1p < 0.05 compared to animals treated with L-Arg; 2p < 0.05 compared 
to animals treated with CoQ10.
Reprogramming of mitochondria metabolism, dis-
orders of redox homeostasis in mitochondria electron 
transport chain are characteristic for malignant tumor 
cells. That is accompanied by the replacement of four- 
to single-electron restoration of oxygen molecule with 
subsequent formation of superoxide radicals. Increased 
production of superoxide radicals in tumor cells 
promotes cancer progression through the activation 
of signaling pathways that regulate metabolic changes, 
proliferation, angiogenesis and metastasis [18, 19].
CoQ10 plays the role of electron transporter in com-
plexes I, II and III electron transport chain of mitochon-
dria. Reduced form of CoQ10 protects the membrane, 
proteins and mitochondrial DNA from oxidative agents, 
including superoxide radicals. We have found that 
CoQ10 realizes its protective function restoring the 
electron transport process and reducing the level 
of generation of superoxide radicals by mitochondria 
in LLC cells. These data are in agreement with the 
data on protective effect of CoQ10 toward UV irradiated 
astrocytes [20] and fibroblasts [21].
Recent studies have shown that NO takes part in the 
regulation of tumor cell proliferation, in particular, in its in-
hibition and induction of apoptosis, which is possible due 
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to the ability of NO to inactivate iron-containing enzyme 
involved in the synthesis of ATP and DNA replication. 
Activation of NO synthase (NOS) and increased levels 
of NO generation can have both antitumor effect, and 
promote the initiation and progression of tumor [2]. 
The use of different doses of NO may allow to regulate 
phenotypic responses through molecular mechanisms 
that form pro- and antitumor effects.
Our results showed a dose-dependent action 
of L-Arg on redox-dependent processes in LLC. Thus, 
the use of L-Arg at high doses leads to increased levels 
of NO and superoxide radicals in mitochondria of LLC 
cells, increasing their cytotoxic effect by formation 
of peroxynitrite, which can cause DNA damage and 
initiation of apoptosis. Similar results were obtained 
in the study of dose-depending action of NO donors 
on proliferation and apoptosis in Ehrlich ascites 
carcinoma [22]. It should be noted that the use 
of NO donors at low doses enhances the functional 
activity of mitochondria, stimulates the formation 
of superoxide radicals in physiological range and, 
conversely, at high doses — depresses mitochodrial 
respiration, inhibits the incorporation of arachidonic 
acid and activates its output.
In modern studies of suppression, stabilization 
or enhancement of the degradation of extracellular 
matrix are considered critical characteristics 
of malignant progression [9] as well as expression 
level of gelatinases is thought to be associated with the 
metastasis and overall survival of cancer patients [10]. 
Known synthetic inhibitors inhibit MMP activity in in vitro 
experiments and in animal models, but failed in clinical 
trials [23]. On the other hand, some stu dies have shown 
that antioxidants [15, 24], inclu ding CoQ10 [25, 26], 
suppress tumor growth by inhibition of MMP activity via 
intracellular regulation of reactive oxygen species. Our 
results showed that MMP-2 and -9 mediate antitumor 
effects of L-Arg and CoQ10 at the level of intercellular 
matrix proteolysis. Redox-regula ted decrease of gela-
tinases activity promotes inhibition of tumor cell migra-
tion, dissemination and formation of metastatic niches.
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